Burzynski Research Institute, Inc. (BZYR)
OTCMKTS · Delayed Price · Currency is USD
0.0250
-0.0130 (-34.21%)
At close: Jan 23, 2026
Burzynski Research Institute Company Description
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers.
The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Burzynski Research Institute, Inc.
| Country | United States |
| Founded | 1977 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Stanislaw Burzynski |
Contact Details
Address: 9432 Katy Freeway Houston, Texas 77055 United States | |
| Phone | 713 335 5697 |
| Website | propcitweb.ddns.net:83 |
Stock Details
| Ticker Symbol | BZYR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | March - February |
| Reporting Currency | USD |
| ISIN Number | US1231591058 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stanislaw R. Burzynski M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Patryk P. Goscianski M.B.A. | Chief Financial Officer, Treasurer and Secretary |
| Dr. Tomasz Janicki M.D. | Vice President of Clinical Trials |